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Abstract
Background: Adults with polycystic ovary syndrome (PCOS) can have multiple metabolic abnormalities. However,
studies in the adolescent population are still limited and these results seem to vary widely. This study was to
investigate the metabolic abnormalities in adolescents with PCOS in South China and the potential risk factors
contributed to these health risks.
Methods: Anthropometric measurements and biochemical parameters were evaluated in 128 adolescents with
PCOS and their age- and BMI-matched controls.
Results: The prevalence of pre-diabetes, insulin resistance, hyperinsulinemia, dyslipidemia and metabolic syndrome
in adolescents with PCOS was 11.7%, 46.9%, 29.7%, 22.7% and 4.7%, respectively. 16.3%, 74.4%, 67.4%, 39.5% and
14% of the PCOS subjects with BMI > 85th had pre-diabetes, insulin resistance, hyperinsulinemia, dyslipidemia and
metabolic syndrome, whereas 9.4%, 32.9%, 10.6%, 14.1% and 0% of the PCOS subjects with BMI < 85th had such
disturbances.
Conclusions: Adolescents with PCOS in South China had more metabolic abnormalities than their age- and BMI-
matched non-PCOS counterparts. Obesity could worsen insulin resistance, hyperinsulinemia and metabolic
syndrome in PCOS adolescents.
Background
Polycystic ovary syndrome (PCOS) is a heterogeneous
endocrine disorder that affects about 6%-8% women
worldwide [1]. The consequences of the PCOS extend
beyond the reproductive axis; women with the disorder
are at substantial risk for developing metabolic abnorm-
alities [2]. Perpetual sequence of hormonal and meta-
bolic aberrations in PCOS patients may commence
early, even in adolescent period, and extend throughout
life.
Metabolic abnormalities, including pre-diabetes, dysli-
pidemia and metabolic syndrome (MS), have been
widely studied in adult women with PCOS. Women
with PCOS tend to have more than two to four times
metabolic disturbances compared to those without
PCOS [3-5]. However, there are few studies on the
metabolic disturbances in adolescents with PCOS all
over the world. Moreover, our previous studies also
found a lower prevalence of the abnormal glucose toler-
ance and MS in Chinese women [6,7]. Therefore, we
sought to exhibit the metabolic abnormalities in adoles-
cents with PCOS.
40-60% of women with PCOS are overweight or obese.
The role of obesity as a contributing factor in the devel-
opment of PCOS has been widely accepted [8]. Body
mass index (BMI) levels correlate with both body fat
and concurrent health risks. Hence, we explored the
relationship between BMI levels and metabolic abnorm-
alities in Chinese adolescents with PCOS.
The aim of this study was to investigate the character-
istics of metabolic abnormalities in adolescents with
PCOS in South China, and to explore their potential
risks, especially obesity. We sought to determine
whether screening adolescents for metabolic abnormal-
ities would benefit.
Methods
Subjects and study design
We performed a cross-sectional study of 128 adolescents
with PCOS recruited from the gynecological outpatient
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department of Memorial Hospital of Sun Yat-Sen Uni-
versity from January 2004 to December 2009. PCOS was
defined by the Rotterdam 2003 criteria [2]. PCOS sub-
jects should present at least two of the following criteria:
oligo- and/or anovulation (i.e. ≤ 8 menstrual periods in
a year or menstrual cycles more than 35 days in length);
clinical hyperandrogenism (i.e. acne or modified Ferri-
man-Gallwey scores ≥ 8) and/or biochemical hyperan-
drogenism (i.e. serum total testosterone(TT) ≥ 2.6
nmol/l, free testosterone (FT) ≥ 6.0 pg/ml, TT and FT
normal values were determined by the clinical labora-
tory of the gynecology department at the Memorial
Hospital of Sun Yat-Sen University); and polycystic
ovaries (i.e. the presence of ≥ 12 follicles in each ovary
measuring 2-9 mm in diameter) after exclusion of other
etiologies (e.g. congenital adrenal hyperplasia, androgen-
secreting tumours and Cushing’s syndrome). The Rot-
terdam criteria have expanded rather than replacing the
NIH criteria, because all women diagnosable by the NIH
1990 criteria would also meet the Rotterdam definition.
This study could analyze two subgroups of PCOS
according to different diagnostic approach.
Age- and BMI-matched controls were recruited from
a total of 654 adolescents visiting the health-care center
for an annual routine check-up. They were asked to fill
out a questionnaire on their menstrual cycle pattern
during last year and received anthropometric measure-
ments. In total, 593 (90.7%) completed, among which
89.4% (530) had normal menstruation (defined by aver-
age length of the menstrual cycle between 21-35 days,
and menstrual period less than 7 days.), but only less
than 100 adolescents participated in further testing.
After exclusion of polycystic ovaries by transrectal ultra-
sound, 40 adolescents served as the age- and BMI-
matched controls.
This study was approved by the institutional review
board of the Hospital. Informed consent was obtained
either from a legal guardian of each subject less than 18
years old or from those subjects 18 years old or older.
Any medications known to affect sex hormone, glucose
or lipid metabolism were discontinued for at least a
month, with the exception of oral contraceptives for
3 months before the study. All subjects did not use any
hypolipidemic or anti-hypertensive drugs.
Study protocols
All subjects who were enrolled in the study had a medi-
cal history and underwent physical examination, includ-
ing weight, height, waist and hip circumferences, blood
pressure, modified Ferriman-Gallwey scores, and acne
scores. All measurements were done by observers
trained with the same standard protocols [9-11]: waist
circumference was measured midway between the low-
est rib and the iliac crest with the subject standing at
the end of gentle expiration, and hip circumference at
the greater trochanters; blood pressure was measured
twice with mercury sphygmomanometer, with subjects
seated quietly for at least 5 minutes, and the readings
were averaged as the final value. Ferriman-Gallwey
scores were assessed by at least two observers; Transrec-
tal ultrasound examination was performed to evaluate
the ovaries using a Toshiba Sonolayer SSA-220A
(Toshiba, Tokyo, Japan) with a mechanical 6-MHz
probe. Adolescents with regularly menstruation were
scanned in the early follicular phase (cycle days 3-5),
while those with oligomenorrhea or amenorrhea were
scanned either at random or between days 3 and 5 after
a progestin-induced withdrawal bleeding.
After a 10-hour overnight fasting, blood samples were
taken from adolescents between the first and fifth day of
the menstrual period/withdrawal bleeding in order to
measure PRL, LH, FSH, estradiol (E2), total testosterone
(TT), free testosterone (FT), sex hormone-binding glo-
bulin (SHBG), DHEAS, 17-OHP, TSH, and lipid profile.
An oral glucose-tolerance test (OGTT) using 75 g of
glucose was then performed, and blood samples were
taken at 0, 60, and 120 min for glucose and insulin mea-
surement. HOMA-IR was calculated as (fasting plasma
glucose (mmol/l)*insulin (mU/ml))/22.5.
Impaired fasting glycaemia (IFG), impaired glucose
tolerance (IGT) and diabetes mellitus (DM) were
defined by the criteria proposed by the American Dia-
betes Association (ADA) [12]. Patients with IFG and/or
IGT are now referred to as pre-diabetes [12]. Dyslipide-
mia was defined as having one or more of the following:
CHOL ≥ 6.0 mmol/L, TG ≥ 1.7 mmol/L, HDL-C < 1.29
mmol/L and LDL-C ≥ 3.6 mmol/L. Insulin resistance
(IR) was defined as the HOMA-IR value ≥ 95th percen-
tile, and hyperinsulinemia (HIN) as the fasting insulin
level ≥ 95th percentile [13]. MS was defined by Interna-
tional Diabetes Federation (IDF) criteria for MS in chil-
dren and adolescent [14,15]. Adult IDF criteria also
apply to adolescents more than 16 years [15], if they
had central obesity (waist circumference ≥ 80 cm) plus
two or more of the following four factors: 1) increased
concentration of TG ≥ 1.7 mmol/l; 2) reduced concen-
tration of HDL-C < 1.29 mmol/l; 3) raised blood pres-
sure: systolic pressure ≥ 130 mmHg or diastolic pressure
≥ 85 mmHg or treatment of previously diagnosed hyper-
tension; and 4) increased fasting glucose level ≥ 5.6
mmol/l or previously diagnosed type 2 diabetes.
Assays
PRL, LH, FSH, E2, and TT were measured by the chemilu-
minescence immunoassays Access 2 (Beckman, USA); FT,
SHBG, DHEAS, and 17-OHP were measured by Access 2
ELISAs (Beckman, USA). TSH was measured using a che-
miluminescence immunometric assay (Immulite 2000
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Analyzer; CPC, Los Angeles, CA, USA). Total cholesterol
(CHOL), high-density lipoprotein cholesterol (HDL-C),
low-density lipoprotein cholesterol (LDL-C) and triglycer-
ide (TG) were measured using an enzymatic calorimetric
method with the 7600 autoanalyzer (Hitachi 7600). Plasma
glucose was measured using the glucose oxidase method
(Hitachi 7600) and plasma insulin using a chemilumines-
cence immunometric assay and commercial kit (Immulite
2000 Analyzer; CPC).
Statistical analysis
All data were analyzed using SPSS version 13.0 (SPSS
Inc., Chicago, IL, USA). We assessed the normality of
the distribution of all continuous variables using the
Kolmogorov-Smirnov test. Because the data were not
normally distributed, continuous variables were pre-
sented as medians and the interquartile ranges. Medians
between patients and controls were compared with the
Mann-Whitney U test. Pearson c2 test was used to ana-
lyze the differences between the groups and obtain




In total, 128 adolescents were diagnosed as PCOS
according to the Rotterdam criteria. Of these, 96.1% pre-
sented oligomenorrhea or amenorrhea, all persisting for
2 years post menarche; 83.6% presented ultrasono-
graphic appearance of polycystic ovaries; 74.2% pre-
sented clinical and/or biochemical hyperandrogenism. In
total, 70.3% (90/128) of patients had both androgen
excess and ovulatory dysfunction and met the NIH 1990
criteria.
The comparison of demographic characteristics
between adolescents with PCOS and controls was sum-
marized (Table 1). No differences were found between
the controls whether had given a blood sample or not,
concerning age, BMI, duration of the period, and quan-
tity of menstrual flow. There were no differences in age,
menarche age, gynecological age, and BMI between the
subjects with and without PCOS. Subjects with PCOS
had increased waist circumference, higher FG scores
and blood pressure. The subjects with PCOS defined by
different criteria presented almost the same results
when compared with controls, except for the waist/hip
ratio.
Table 2 listed the hormonal and metabolic features of
adolescents with or without PCOS. Subjects with PCOS
displayed significantly higher LH, TT, FT, 2-h glucose,
fasting insulin, 2-h insulin, and HOMA-IR, but there
were no significant differences in FSH, fasting glucose,
TG, CHOL, LDL and HDL between the PCOS and the
control groups.
Prevalence of metabolic abnormalities in adolescents with
and without PCOS
The prevalence of various metabolic abnormalities in
adolescents with and without PCOS was listed in Table
3. No DM was detected either in the PCOS group or in
the control group. Pre-diabetes (IFG and/or IGT) was
only found in the PCOS group, and the prevalence of
Table 1 Demographic characteristics of adolescents with
and without PCOS
PCOS




Age(yr) 19.0 (17.0-19.0) 18.0 (17.0-19.0) 18.0 (17.0-19.0)
Menarche(year) 12.5 (12.0-13.0) 12.0 (12.0-13.0) 12.0 (12.0-13.0)
Gynecological
age(year)
6.0 (4.0-7.0) 6.0 (5.0-7.0) 6.0 (5.0-7.0)
BMI(kg/m2) 19.6 (18.4-21.0) 20.0 (18.5-25.1) 20.2 (18.4-25.2)
Waist(cm) 67.3 (63.0-72.8) 72.0 (67.5-80.0) ** 72.0 (68.0-80.4) **
WHR 0.78 (0.75-0.81) 0.80(0.76-0.84) 0.80(0.76-0.85) *
SBP(mmHg) 100.0 (92-105) 110.0 (100-120) ** 110.0 (98-120) **
DBP(mmHg) 60.0 (60-66) 71.0 (65-78) ** 71.0 (65-78) **
FG scores 0 (0-5.5) 9 (6-13) ** 10 (7-13) **
Variables were expressed as median with (interquartile range).
Gynecological age = calendar age - menarche age; BMI: body mass index;
WHR: waist to hip ratio; SBP: systolic pressure; DBP: diastolic pressure; FG
scores: Ferriman-Gallwey scores.
*P < 0.05, **P < 0.01 vs. control.
Table 2 Hormonal and metabolic features of adolescents





FSH (IU/L) 5.3 (4.4-6.6) 5.6 (4.5-6.9) 5.6 (4.5-6.9)
LH (IU/L) 5.1 (3.6-7.5) 11.0 (5.9-16.1) ** 10.3 (6.3-16.2) **
TT (nmol/L) 1.7 (1.5-2.4) 2.5 (2.0-3.2) ** 2.8 (2.3-3.3) **
FT (pg/ml) 2.9 (2.1-3.5) 4.6 (2.6-7.3) ** 5.1 (2.9-8.1) **
Fasting glucose
(mmol/L)
4.7 (4.5-4.8) 4.8 (4.5-5.0) 4.8 (4.5-5.1)
2-h glucose
(mmol/L)
5.6 (5.0-6.3) 6.3 (5.1-7.1) * 6.3 (5.3-7.1) **
Fasting insulin
(μU/ml)
5.7 (4.4-8.3) 8.8 (5.7-13.2) ** 9.0 (5.9-13.2) **
2-h insulin
(μU/ml)
48.1 (35.5-82.4) 72.7 (46.6-131.9)* 76.7 (51.0-139.)**
HOMA-IR 1.2 (0.9-1.8) 1.9 (1.2-2.9) ** 1.9 (1.4-2.9) **
CHOL (mmol/L) 4.2 (3.7-4.7) 4.5 (4.1-5.1) 4.5 (4.1-5.1)
TG (mmol/L) 0.9 (0.7-1.2) 1.0 (0.8-1.3) 1.0 (0.7-1.3)
HDL (mmol/L) 1.6 (1.4-1.7) 1.6 (1.4-1.9) 1.5 (1.3-1.9)
LDL (mmol/L) 2.6 (2.1-2.9) 2.5 (2.1-3.1) 2.5 (2.1-3.2)
Variables were expressed as median with (interquartile range).
FSH: follicle stimulating hormone; LH: luteinizing hormone; TT: total
testosterone; FT: free testosterone; HOMA-IR: Homeostasis Model Assessment
of Insulin Resistance; CHOL: total cholesterol; TG: triglyceride; HDL: high-
density lipoprotein cholesterol; LDL: low-density lipoprotein cholesterol.
*P < 0.05, **P < 0.01 vs. control.
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IFG, IGT and pre-diabetes was 1.6%, 10.2% and 11.7%,
respectively. The prevalence of hyperinsulinemia and
insulin resistance raised more than 2.5 folds in PCOS
group (29.7% vs. 7.5%; 46.9% vs.17.5%). PCOS group
also presented higher prevalence of central obese (20.3%
vs. 5%). However, there were no significant differences
in lipid disturbances and other components of MS
between groups. The characteristics were consistent, no
matter which diagnostic criteria were used to define
PCOS.
Prevalence of metabolism abnormalities in different BMI
subgroups of adolescents with PCOS
Of the sample of 530 otherwise healthy adolescents, the
85th and 95th percentile of BMI was 21.4 kg/m2 and
23.8 kg/m2, respectively. 33.6% (43/128) subjects with
PCOS by Rotterdam criteria had a higher BMI above
the 85th percentile, and 36.7% (33/90) subjects by NIH
criteria.
To assess the effect of BMI on the prevalence of pre-
diabetes, dyslipidemia and metabolic syndrome, the sub-
jects with PCOS were then divided into two groups,
group BMI ≥ 85th and group BMI < 85th. Although
there was no statistical significance in pre-diabetes and
hypercholesterolemia between the two groups (Table 4),
group BMI ≥ 85th had higher risk of hyperinsulinemia
(67.4% vs. 10.6%; OR, 17.5; 95%CI, 6.8-44.8), insulin
resistance (74.4% vs. 32.9%; OR, 5.9; 95%CI, 2.6-13.5),
and dyslipidemia (39.5% vs. 14.1%; OR, 4.0; 95%CI, 1.7-
9.4) than those of group BMI < 85th (Figure 1).
Moreover, metabolic syndrome was only detected in
group BMI ≥ 85th.
Discussion
PCOS can have multiple metabolic disturbances, such as
insulin resistance and compensatory hyperinsulinemia,
impaired glucose tolerance, dyslipidemia and metabolic
syndrome [16]. Concerning the long-term health risk, it
is necessary to identify such metabolic disorders in
those adolescents with PCOS as early as possible. How-
ever, data on metabolic disturbances in adolescents with
PCOS are limited, and the results seemed to vary in stu-
dies of different populations. In this study, we first
Table 3 Prevalence of various metabolic abnormalities in
adolescents with and without PCOS
PCOS (%)
Control (%) Rotterdam criteria NIH criteria
IFG 0 1.6 2.2
IGT 0 10.2* 12.2*
Pre-diabetes 0 11.7* 14.4**
HIN 7.5 29.7** 33.3**
IR 17.5 46.9** 44.4**
Hypercholesterolemia 0 4.7 5.6
Elevated LDL 0 4.7 5.6
Low HDL 15.0 14.1 16.7
Hypertriglyceridemia 7.5 10.2 12.2
Dyslipidemia 17.5 22.7 26.7
Central obese 5.0 20.3* 24.4**
Raised BP 2.5 8.0 8.2
MS 2.5 4.7 6.7
IFG: impaired fasting glycaemia; IGT: impaired glucose tolerance; pre-diabetes:
IFG and/or IGT; HIN: hyperinsulinemia; IR: insulin resistance; MS: metabolic
syndrome.
*P < 0.05, **P < 0.01 vs. control.
Table 4 Prevalence of metabolic abnormalities in
adolescents with PCOS categorized by different BMI
Rotterdam criteria NIH criteria
BMI < 85th ≥ 85th < 85th ≥ 85th
Number of subjects 85 43 57 33
IFG 2.4 0 3.5 0
IGT 7.1 16.3 10.5 15.2
pre-diabetes 9.4 16.3 14.0 15.2
HIN 10.6 67.4 *** 12.3 69.7 ***
IR 32.9 74.4 *** 28.1 72.7 ***
Hypercholesterolemia 2.4 9.3 3.5 9.1
Elevated LDL 1.2 11.6* 1.8 12.1
Low HDL 8.2 25.6** 10.5 27.3 *
Hypertriglyceridemia 3.5 23.3 ** 3.5 27.3**
Dyslipidemia 14.1 39.5** 17.5 42.4 *
Central obese 0 60.5 *** 0 66.7 ***
Raised BP 0 19.4** 0 18.5 *
MS 0 14.0 ** 0 18.2**
Abbreviations as in Table 3.
*P < 0.05, **P < 0.01, ***P < 0.001 vs. the “BMI < 85th” value.
Figure 1 Odds ratio for four clinical disorders in BMI ≥85th
versus BMI < 85th groups of adolescents with PCOS. PCOS was
defined by Rotterdam criteria.
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outlined the metabolic disturbances in Chinese adoles-
cents with PCOS, and then we also studied the potential
risk factors in such population.
Our data showed that the prevalence of IFG and IGT
was 1.6% and 10.2%, respectively. No T2DM was
detected. A Canadian study of 22 obese adolescents with
PCOS showed only one patient (4.5%) suffered from
IGT [17]. In contrast, two American studies from a
similar geographic background population both indi-
cated a higher prevalence of IGT in obese adolescents
with PCOS (29.6%, 8 in 27 [18]; 27.3%, 3 in 11 [19],
respectively). Considering the confounding effects of
ethnicity and geographical background on the preva-
lence of metabolic disturbances, we also searched litera-
tures published by Asian researchers, and only found
one Korean study in which 1 in 16 (6.3%) adolescents
with PCOS had IGT [20]. In fact, the variations among
these studies may due to the small sample size of sub-
jects. However, a study report of 101 overweight Hispa-
nic adolescents revealed that the prevalence of IGT and
DM was 6.6% and 2%, respectively [21]. In our study,
the prevalence of IGT among overweight (BMI ≥ 85th
according to pediatric criteria [22]) subjects with PCOS
was 16.3%. Considering more detail of the different
study population, the variation may due to the elder age
in our study population.
Data from Nur et al [21] and our study indicated ado-
lescents with PCOS had a lower prevalence of either
pre-diabetes or T2DM than their same ethnicity and
geographical background adults. The prevalence of IGT
was 31-35% in adults, while DM was 7.5-10% [23,24].
Although in our previous study the prevalence in Chi-
nese adults with PCOS was lower (IGT 20.5%,
T2DM1.9%) than that of American PCOS [6], the preva-
lence was still higher than that of Chinese adolescents.
Given that the conversion from IGT to T2DM is sub-
stantially enhanced in women with PCOS [25,26], the
early identification of affected patients and institution of
lifestyle changes or drug treatments may benefit. Like
other studies, we noted that the fasting glucose failed to
predict the majority of the subjects with IGT, confirm-
ing the recommendation that the most reliable screening
test for IGT in PCOS adolescents is the 2-h OGTT after
a 75 g glucose load [3].
The prevalence of MS, diagnosed by IDF criteria, was
4.7% in the studied Chinese adolescents with PCOS.
Metabolic disorders were common in these adolescents
as more than one third of them exhibited at least one
component of MS. Central obesity and dyslipidemia
were the two most common metabolic features, which
was also the case in adult PCOS patients according to
our previous study [7]. A study of 49 white of non-
Hispanic adolescents with PCOS revealed the prevalence
of MS was 37%; the mean BMI of such population was
32 kg/m2 [27]. In India, 17 in 39 (43.6%) subjects with
mean BMI 29.3 kg/m2 suffered from MS [28]. While the
subjects with BMI 25 kg/m2, the prevalence reported in
Italy was 9.4% (5 in 53) [29]. Taken together all these
results evidence that the MS can be found in PCOS
women as early as in adolescence, however, the exact
prevalence is not sure. The difference may due to sev-
eral factors. First, there are no consistent criteria for the
diagnosis of MS in adolescents. Important demographic
and clinical differences exist in the typology of MS,
depending on the definition [30-32]. Second, the ranges
of age in these studies are quite different. Age is
regarded as an important risk factor for MS in both the
general population and PCOS patients. Data of our pre-
vious study indicated the increasing trend in the preva-
lence of MS [7]. Moreover, age could affect the diagnosis
of PCOS, because of the physiologic irregular ovulation,
insulin resistance, and multi-follicular ovarian morphol-
ogy characteristic of normal adolescents. Thus, the diag-
nosis of PCOS in young adolescents should be prudent
[33,34]. Third, obesity is an early step in the etiological
cascade leading to full metabolic syndrome. Increased
body weight in female significantly increases the risk of
having MS [35]. Difference BMI levels could account for
variations in the prevalence of MS. Other factors, such as
sample size, genetic factors, dietary, exercise and geo-
graphic location may also have some effects.
In this study, the characteristics of metabolic distur-
bances also exhibited according to different diagnosis
criteria for PCOS. Specialized criteria for the diagnosis
of PCOS in adolescents have not been established yet,
and instead, the diagnostic criteria for adults are used in
clinical practice. At present, the 2003 Rotterdam criteria
are more widely accepted than the NIH criteria, but the
former tends to expand rather than replace the latter
because all women diagnosed by the NIH 1990 criteria
would also meet the Rotterdam criteria. The risk of
metabolic disturbances may vary among different phe-
notypes of PCOS based on the Rotterdam criteria.
Adults PCOS defined by NIH criteria had more severe
metabolic abnormalities than those defined by Rotter-
dam criteria. The difference of prevalence of obesity and
androgen excess may attribute to the characteristic
[36-38]. In an attempt to avoid erroneous diagnoses, we
decided to enroll female adolescents with more than
two gynecologic years because a normalization of men-
strual cycles mainly occurs within the first 2 years after
menarche [39,40]. In our group, the median gynecologic
age was 6 years. There were no significant differences in
metabolic abnormities between the two groups categor-
ized by two different criteria. In total, 70.3% (90 in 128)
subjects met both the criteria. The number of non-NIH
subjects group was small, which may weaken the power
to detect the differences of metabolic features.
Huang et al. Reproductive Biology and Endocrinology 2010, 8:142
http://www.rbej.com/content/8/1/142
Page 5 of 7
Moreover, there were similar levels of BMI, FG score,
TT and FT between the Rotterdam group and NIH
group. Considering the effects of BMI and androgen on
metabolic abnormities, it was not surprising to fail to
detected the differences in the two groups PCOS.
Nearly 50% of PCOS patients suffer from obesity,
although it is not included in the diagnostic criteria.
Obesity contributes to the manifestations of PCOS by
increasing the magnitude of hyperandrogenism and the
rates of anovulatory cycles and infertility. The pathophy-
siologic mechanism is related to hyperinsulinemia
which, in turn, is induced by insulin resistance [41].
Although many patients with PCOS had insulin resis-
tance independent of obesity [42,43], the obesity indeed
worsen underlying insulin resistance and insulin resis-
tance-associated reproductive and metabolic features.
Our study suggested that, when matched for obesity,
PCOS was associated with increased risks of insulin
resistance, hyperinsulinemia and pre-diabetes, but was
not associated with an increased risk of MS. Further
analysis of PCOS subjects revealed that obesity was
associated with increased risks of insulin resistance,
hyperinsulinemia and MS, but was not associated with
pre-diabetes. The PCOS status and obesity are both
associated with the higher prevalence of insulin resis-
tance and hyperinsulinemia. As a central pathogenetic
feature of PCOS, insulin resistance could be worsened
by obesity. And the impact of obesity is a more signifi-
cant contributor to the prevalence of MS than PCOS
status. In a word, our study emphasized the importance
of PCOS status and obesity in adolescents.
Study limitation
Because of the cross-sectional design and modest sam-
ple size of the present study, we could not be certain
whether these markers showed ethnic variation in their
relation to clinical events such as MS. This would
require a much larger prospective study of metabolic
disorders in each of several ethnic groups. And due to
the difficulties in inviting healthy adolescents to partici-
pate in the study, especially scaring of the transrectal
ultrasound, uncomfortable and time-consuming OGTT
test, there were limit controls fulfill all test.
Conclusions
Adolescents with PCOS in South China had more meta-
bolic abnormalities than their age- and BMI-matched
non-PCOS counterparts. Obesity could worsen insulin
resistance, hyperinsulinemia and metabolic syndrome in
PCOS adolescents.
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